Moderna, Inc. (BMV:MRNA)
Mexico · Delayed Price · Currency is MXN | Market Cap | 1.65T +725.5% |
| Revenue (ttm) | 38.93B -27.6% |
| Net Income | -55.06B |
| EPS | -139.92 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,424 |
| Open | 3,525.00 |
| Previous Close | 3,546.49 |
| Day's Range | 3,452.61 - 3,600.00 |
| 52-Week Range | 414.00 - 3,730.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 5, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provid... [Read more]
Financial Performance
In 2025, Moderna's revenue was $1.94 billion, a decrease of -39.93% compared to the previous year's $3.24 billion. Losses were -$2.82 billion, -20.75% less than in 2024.
Financial numbers in USD Financial StatementsNews
Moderna Stock (MRNA) Climbs 13% to Top Its 52-Week High — Here’s Why
Moderna shares ($MRNA) climbed by 13% to around $223 on Friday afternoon, pushing the U.S. biotech and pharma company past its one-year high of $212.22. The rally came as the…
Moderna stock fires past 52-week high: what's behind Friday's rally?
Moderna MRNA shares jumped more than 9% in early trading Friday, reaching a fresh 52-week high as the biotechnology company returned to the Nasdaq-100 index. Moderna hit a 52-week high of $216.95.
Moderna price target raised to $200 from $170 at BofA
BofA raised the firm’s price target on Moderna (MRNA) to $200 from $170 and keeps a Neutral rating on the shares as part of a Q3 earnings preview for the…
Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets
The healthcare sector stood out as one of the few bright spots in Wednesday's trading.
Moderna price target raised to $95 from $89 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Moderna (MRNA) to $95 from $89 and keeps an Equal Weight rating on the shares. The firm adjusted its models for its…
Tempus AI announces multi-year collaboration with Moderna, Merck
Tempus (TEM) announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene, a novel, potential first-in-class individualized neoantigen therapy bein...
Why Is Moderna Stock (MRNA) Falling Today, October 6?
Shares of U.S. vaccine maker Moderna ($MRNA) fell about 7% to around $190 on Tuesday afternoon. This followed an update from the World Health Organization (WHO) about the suspected plague…
Moderna stock rises 2% on Nasdaq 100 entry but this analyst says sell
Moderna stock (NASDAQ: MRNA) rose more than 2% in early premarket trading on Friday after Nasdaq said the biotech company will join the Nasdaq-100 next week, creating new demand from index-tracking fu...
Nike, ON Semi, Moderna, and More Stocks That Explain Today's Market
Nike slumps after the retailer misses analysts' first-quarter earnings target and issues downbeat full-year guidance.
Why Did Moderna Stock Gain (MRNA) in After-Hours Trading on Thursday?
Moderna ($MRNA) stock inched higher by 0.16% in after-hours trading on Thursday after falling 1.89% during the regular session. The move came after Nasdaq announced that Moderna will join the…
Moderna to replace Warner Bros Discovery on Nasdaq 100
Nasdaq said on Thursday that vaccine maker Moderna will replace Warner Bros. Discovery on the Nasdaq 100 index , effective October 9.
Moderna to join Nasdaq-100 Index
Nasdaq announced that Moderna (MRNA) will become a component of the Nasdaq-100 Index replacing Warner Bros. Discovery, Inc. (WBD) prior to market open on Friday, October 9, 2026. Published first…
Moderna Stock Slumps as Citi Says It's Time to Sell After 500% Rally This Year
Moderna's stock has been flying high lately. That has one group of analysts saying it's time to sell.
Moderna and Fair Isaac: The Best and Worst S&P 500 Stocks for the Third Quarter
Moderna stock has rallied since the company unveiled clinical updates to its cancer vaccine in collaboration with Merck in late August.
Wednesday's First Moves: MRNA Downgrade, BA Jet Contract, JBL Earnings
Citi downgraded Moderna (MRNA) following the stock's astronomical rally in recent weeks. Boeing (BA) pens a $20 billion deal with the U.S. Navy for its next generation fighter jets.
Moderna stock falls 6% in premarket: here's why
Moderna stock MRNA fell nearly 6% in premarket trading on Wednesday after Citi downgraded the biotech company to ‘Sell' from ‘Hold', citing concerns that its recent valuation is difficult to justify. ...
Moderna Stock Has Run Too Far, Too Fast. Why Citi Just Downgraded It to Sell.
Citi downgrades Moderna to Sell from Hold, saying the data around its cancer vaccine, instimeran autogene, isn't enough to justify the valuation.
Citi tells investors it's time to sell Moderna after 600%-plus stock gains
Revenue and profit forecasts fail to justify the hype baked into Moderna's share price, according to Citi's analysts.
The Top HealthTech Questions Landing on Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled th...
Moderna Adds Chief Operating Officer Role as Company Expands into Oncology
Juan Andres to Return to Moderna as Chief Operating Officer Jerh Collins to Retire Following Four Years of Leadership at Moderna CAMBRIDGE, MA / ACCESS Newswire / September 30, 2026 / Moderna, Inc. (N...
Moderna CEO's Realistic Approach to Innovation
Moderna's share price popped in August on positive news about its therapeutic cancer vaccine to prevent melanoma from recurring. At Journal House, United Nations General Assembly yesterday, the Journa...
Moderna CEO's Surprising Comment Gives Clues About Where Drugmaker Is Going Next
Moderna stock heads for its highest close since 2023 after CEO Stéphane Bancel says the drugmaker ‘has never been' just a Covid vaccine company.
Moderna Transcript: Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
The forum highlighted a shift from a COVID-19 focus to a broad mRNA platform spanning vaccines, oncology, rare diseases, and autoimmune therapies. Key advances include intismeran's strong phase III results, expansion into new indications, and a robust pipeline supported by proprietary manufacturing and AI-driven R&D.
Moderna will reveal the data for its mRNA cancer vaccine next month. Here's why it matters.
One reason that analysts and doctors want to see the data is to better understand how well the personalized treatment works.
Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
Phase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected for presentation at a Presidential Symposium Moderna to host an investor event v...